Therefore, this study demonstrates that combining a novel MDM2 inhibitor XR-2 [22] and NMD inhibitor (NMDi) could activate p53α and p53β, respectively, and have significant synergistic effects on TP53 wild-type cancer cells. The gene discussed is PLA1A; the disease is cancer.